<DOC>
	<DOCNO>NCT01276522</DOCNO>
	<brief_summary>Schnitzler syndrome disable inflammatory disease , characterize chronic urticaria , fever , arthralgia , bone pain gammopathy , far effectively treat anakinra , interleukin-1 receptor antagonist . However , drug register use Schnitzler syndrome , need inject daily , uncomfortable unpractical . Therefore treatment target IL-1 need . Canakinumab long-acting monoclonal antibody IL-1β register bimonthly use rare autoinflammatory disease Cryopyrin-associated periodic syndrome ( CAPS ) . We hypothesize effective Schnitzler syndrome view clinical similarity CAPS target IL-1B , also block anakinra ( blocks IL-1B IL-1A ) . This 6-month open-label , single treatment arm study canakinumab 150 300 mg ( case insufficient response 150 mg ) subcutaneous injection per month patient active Schnitzler syndrome , efficacy safety assess .</brief_summary>
	<brief_title>Efficacy Safety Canakinumab Schnitzler Syndrome</brief_title>
	<detailed_description>More Canakinumab : Canakinumab high-affinity human monoclonal anti-human interleukin-1β ( IL-1β ) antibody IgG1/k isotype ) , develop treatment IL-1β driven inflammatory disease . Canakinumab bind human IL-1β functionally neutralize bioactivity pro-inflammatory cytokine . IL-1β produce mainly mononuclear phagocyte response injury infection play dominant role pathobiology autoinflammatory syndrome ( e.g . Cryopyrin associate periodic syndrome , CAPS ) , systemic Juvenile Idiopathic Arthritis gout . Canakinumab expect treat sign symptom inflammation underlie structural damage disease . Canakinumab administer clinical trial intravenous ( i.v . ) infusion subcutaneous ( sc ) injection approve trade name ILARIS® US patient ≥ 4 year age CAPS European Union Switzerland CAPS patient ≥ 4 year age .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Schnitzler Syndrome</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients diagnosis Schnitzler syndrome per criterion ( ref 1 ) . Patients / treat Anakinra must demonstrate partial complete clinical response associate normalization biomarkers inflammation ( CRP ) . Male female patient least 18 year age time screen visit . Patient 's informed consent . Negative QuantiFERON test negative Purified Protein Derivative ( PPD ) test ( &lt; 5 mm induration ) screening within 1 month prior screen visit , accord national guideline . Patients positive PPD test ( ≥ 5 mm induration ) screening may enrol either negative chest xray negative QuantiFERON test ( QFTTB G InTube ) . Adequate contraception premenopausal females Pregnant nursing ( lactate ) woman History immunocompromised , include positive HIV screening ( ELISA Western blot ) . Serologic evidence hepatitis B C infection Live vaccination within 3 month prior start trial , trial , 3 month follow last dose History significant medical condition , Investigator 's opinion would exclude patient participate trial History recurrent and/or evidence active bacterial , fungal , viral infection ( ) Use follow therapy : Anakinra within 24 hour prior Baseline visit XML File Identifier : tl8ybe8lI1o6DeawQocCBa8TF/w= Corticosteroids ( oral prednisone ( equivalent ) ) &gt; 1.0 mg/kg/day ( great maximum 60 mg/day child 60 kg ) within 3 day prior Baseline visit Intraarticular , periarticular intramuscular corticosteroid injection within 4 week prior Baseline visit Any investigational biologics within 8 week prior Baseline visit Any investigational drug , investigational biologic treatment , within 30 day ( 3 month investigational monoclonal antibody ) 5 halflives prior Baseline visit , whichever long History hypersensitivity study drug drug similar chemical class</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Schnitzler syndrome</keyword>
	<keyword>IL-1 beta</keyword>
	<keyword>Canakinumab</keyword>
	<keyword>Ilaris</keyword>
	<keyword>Treatment</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>